BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31821365)

  • 1. HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco.
    Page K; Evans JL; Hahn JA; Vickerman P; Shiboski S; Morris MD
    PLoS One; 2019; 14(12):e0226166. PubMed ID: 31821365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in sources and sharing of needles among people who inject drugs, San Francisco, 2005-2012.
    Kim NJ; Jin H; McFarland W; Raymond HF
    Int J Drug Policy; 2015 Dec; 26(12):1238-43. PubMed ID: 26365768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in San Francisco, CA.
    Morris MD; Evans J; Montgomery M; Yu M; Briceno A; Page K; Hahn JA
    PLoS One; 2014; 9(10):e109282. PubMed ID: 25286346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance of risk behavior reporting within HCV serodiscordant injecting partnerships of young injection drug users in San Francisco, CA.
    Evans JL; Morris MD; Yu M; Page K; Hahn JA
    Drug Alcohol Depend; 2014 Sep; 142():239-44. PubMed ID: 25034898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a novel scale for measuring interpersonal factors underlying injection drug using behaviours among injecting partnerships.
    Morris MD; Neilands TB; Andrew E; Maher L; Page KA; Hahn JA
    Int J Drug Policy; 2017 Oct; 48():54-62. PubMed ID: 28804051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus risk behaviors within the partnerships of young injecting drug users.
    Hahn JA; Evans JL; Davidson PJ; Lum PJ; Page K
    Addiction; 2010 Jul; 105(7):1254-64. PubMed ID: 20491725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco.
    Hahn JA; Page-Shafer K; Lum PJ; Ochoa K; Moss AR
    Hepatology; 2001 Jul; 34(1):180-7. PubMed ID: 11431749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration.
    Morris MD; Shiboski S; Bruneau J; Hahn JA; Hellard M; Prins M; Cox AL; Dore G; Grebely J; Kim AY; Lauer GM; Lloyd A; Rice T; Shoukry N; Maher L; Page K;
    Clin Infect Dis; 2017 Apr; 64(7):860-869. PubMed ID: 28362947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics associated with HIV and hepatitis C seroprevalence among sexual and injecting partners of HIV positive persons who inject drugs in Nairobi and coastal Kenya.
    Sambai BC; Kingston H; Monroe-Wise A; Mbogo L; Juma E; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Scott J; Bosire R; Dunbar M; Macharia P; Masyuko S; Sinkele W; Herbeck JT; Farquhar C
    BMC Infect Dis; 2022 Jan; 22(1):73. PubMed ID: 35062890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injection partnership characteristics and HCV status associations with syringe and equipment sharing among people who inject drugs.
    Mackesy-Amiti ME; Boodram B; Page K; Latkin C
    BMC Public Health; 2023 Jun; 23(1):1191. PubMed ID: 37340398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study).
    Evans JL; Hahn JA; Page-Shafer K; Lum PJ; Stein ES; Davidson PJ; Moss AR
    J Urban Health; 2003 Mar; 80(1):137-46. PubMed ID: 12612103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "To share or not to share?" Serosorting by hepatitis C status in the sharing of drug injection equipment among NHBS-IDU2 participants.
    Smith BD; Jewett A; Burt RD; Zibbell JE; Yartel AK; DiNenno E
    J Infect Dis; 2013 Dec; 208(12):1934-42. PubMed ID: 24136794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montréal, Canada.
    Fortier E; Artenie AA; Zang G; Jutras-Aswad D; Roy É; Grebely J; Bruneau J
    Addiction; 2019 Aug; 114(8):1495-1503. PubMed ID: 30957310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada.
    Jacka B; Roy É; Høj S; Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Bruneau J
    J Viral Hepat; 2019 Dec; 26(12):1413-1422. PubMed ID: 31433888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of assisted partner services for people who inject drugs in Kenya to identify partners living with HIV and hepatitis C virus infection: a prospective cohort study.
    Monroe-Wise A; Mbogo L; Sambai B; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Masyuko S; Scott J; Juma E; Macharia P; Kingston H; Sinkele W; Gitau E; Bosire R; Musyoki H; Herbeck J; Farquhar C
    Lancet Glob Health; 2024 May; 12(5):e859-e867. PubMed ID: 38614633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
    Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
    BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California.
    Horyniak D; Wagner KD; Armenta RF; Cuevas-Mota J; Hendrickson E; Garfein RS
    Int J Drug Policy; 2017 Sep; 47():9-17. PubMed ID: 28683432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
    Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J;
    Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada.
    Fortier E; Høj SB; Sylvestre MP; Artenie AA; Minoyan N; Jutras-Aswad D; Grebely J; Bruneau J
    Int J Drug Policy; 2021 Oct; 96():103439. PubMed ID: 34518099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use.
    Des Jarlais DC; Arasteh K; Feelemyer J; McKnight C; Barnes DM; Perlman DC; Uuskula A; Cooper HLF; Tross S
    Drug Alcohol Depend; 2018 Nov; 192():74-79. PubMed ID: 30243142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.